We research, we develop, we bring true innovations to the marketplace. Is that also your goal? Do you also want to sustainably improve the lives of our patients?
Are you an innovative researcher, an unconventional thinker, a strategist, a visionary, a creative thinker, a pragmatist, or a go-getter? In short, are you a person who will rise to the challenge and make a difference?
Then we look forward to telling you more about Grünenthal—about us, what makes us tick, and how we can reach our goals together - every day, worldwide.
Aachen, Germany, June 12, 2018 – Grünenthal announced today that first patients have been enrolled in two trials of the company’s pivotal phase III program investigating neridronate for the treatment of Complex Regional Pain Syndrome (CRPS). These two trials, KF7013-02 and KF7013-04, are investigating the efficacy and safety of neridronate in 360 patients with CRPS. Neridronate, a bisphosphonate, is an innovative investigational medicine discovered and developed by Abiogen Pharma and now being further developed by Grünenthal for the US territory.
Aachen, Germany, 23 April 2018 – Grünenthal announced today that Philip Just Larsen has been appointed Chief Scientific Officer (CSO) and Member of the Corporate Executive Board. He will assume leadership of Grünenthal’s research and development organization on 1 July 2018. Currently, Philip holds the role of Global Head of Diabetes Research and Translational Medicine and Chief Scientific Officer at Sanofi’s German Hub in Frankfurt.